Roche signs immune checkpoint deal with Curadev
Executive Summary
Curadev Pharma Pvt. Ltd. licensed Roche exclusive rights to develop its preclinical indoleamine 2,3-dioxygenase (IDO1) and tryptophan 2,3-dioxygenase (TDO) immune checkpoint inhibitor, which may be used as either as a monotherapy or in combination with a Roche oncology drug. The partners will also collaborate on R&D of IDO1/TDO blockers.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice